

## **Statement regarding use of non-GAAP financial measures**

In this press release, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached schedules.

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets: Represents recurring amortization charges resulting from the acquisition of intangible assets, including developed technology and database rights.
- Impairment of goodwill and intangible: One-time impairment charges on intangible assets and goodwill tied to company acquisitions from prior years.
- Equity compensation – non-cash equity-based compensation provided to Myriad employees. • Transformation initiatives – transitory costs such as consulting and professional fees related to Myriad's Elevate 2020 program and transformation initiatives.
- Other adjustments – Other one-time non-recurring expenses including expenses related to leadership transition, expenses related to non-recurring severance and retention agreements, non-recurring legal expenses and potential future consideration related to acquisitions from prior years.
- Tax impact associated with non-GAAP adjustments – Tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and CARES Act legislation.

The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

**Reconciliation of GAAP to Non-GAAP Financial Measures  
for the Three Months Ended March 31, 2021 and 2020**  
(unaudited data in millions, except per share amount)

	Three Months Ended March 31,	
	2021	2020
<b>Adjusted Gross Margin</b>		
GAAP Gross Profit <sup>(1)</sup>	\$ 122.8	\$ 113.9
Equity compensation	0.3	0.4
Other adjustments	0.6	—
Adjusted Gross Profit	\$ 123.7	\$ 114.3
Adjusted Gross Margin	71.5%	69.7%

(1) Consists of total revenues less cost of molecular diagnostic testing and cost of pharmaceutical and clinical services from the condensed consolidated statements of operations.

	Three Months Ended March 31,	
	2021	2020
<b>Adjusted Operating Expenses</b>		
GAAP Operating Expenses <sup>(2)</sup>	\$ 169.5	\$ 247.6
Acquisition - amortization of intangible assets	(15.2)	(15.1)
Impairment of goodwill and intangibles	—	(98.4)
Equity compensation	(8.5)	(7.9)
Transformation initiatives	(7.5)	(2.8)
Other adjustments	(11.3)	2.3
Adjusted Operating Expenses	\$ 127.0	\$ 125.7

(2) Consists of research and development expense, change in the fair value of contingent consideration, selling, general, and administrative expense, and goodwill and intangible asset impairment charges from the condensed consolidated statements of operations.

	Three Months Ended March 31,	
	2021	2020
<b>Adjusted Operating Loss</b>		
GAAP Operating Loss	\$ (46.7)	\$ (133.7)
Acquisition - amortization of intangible assets	15.2	15.1
Impairment of goodwill and intangibles	—	98.4
Equity compensation	8.8	7.5
Transformation initiatives	7.5	2.8
Other adjustments	11.9	(2.3)
Adjusted Operating Loss	\$ (3.3)	\$ (12.2)

	Three Months Ended March 31,	
	2021	2020
<b>Adjusted Net Loss</b>		
GAAP Net Loss Attributable to Myriad Genetics, Inc. Stockholders	\$ (39.5)	\$ (115.2)
Acquisition - amortization of intangible assets	15.2	15.1
Impairment of goodwill and intangibles	—	98.4
Equity compensation	8.8	7.5
Transformation initiatives	7.5	2.8
Other adjustments	11.9	(3.3)
Tax impact of non-GAAP adjustments	(8.8)	(11.6)
Adjusted Net Loss	\$ (4.9)	\$ (6.3)
Weighted average shares outstanding	76.0	74.5
Adjusted Net Loss Per Share	\$ (0.06)	\$ (0.08)

**Adjusted Free Cash Flow Reconciliation**  
**for the Three Months Ended March 31, 2021 and 2020**

*(unaudited data in millions)*

	<b>Three Months Ended March 31,</b>	
	<b>2021</b>	<b>2020</b>
<b>Cash flow from operations</b>	\$ 71.8	\$ 16.8
Capital expenditures	(7.1)	(3.0)
<b>Free cash flow</b>	<b>\$ 64.7</b>	<b>\$ 13.8</b>
Transformation initiative costs	7.1	2.8
Other adjustments	0.2	—
Tax effect associated with non-GAAP adjustments	(1.8)	(0.8)
<b>Adjusted Free cash flow</b>	<b>\$ 70.2</b>	<b>\$ 15.8</b>